About
Sudhir Agrawal is founder and president of ARNAY Sciences LLC, a life science research practice specializing in the chemical engineering of oligonucleotides for RNA therapeutic applications. Over 35 years, his research has focused on discovering and developing RNA therapeutics, with work in gapmer antisense, exon skipping, and immune modulation through toll-like receptors. His recent research explores transient spatial cyclic structures of nucleic acids for RNA therapeutic development.
Experience
- ARNAY SciencesFounder and Presidentcurrent2017 — presentMassachusetts, United States
- Quiver BioscienceMember, Scientific Advisory Boardcurrent2024 — presentCambridge, MA
- Aldebaran TherapeuticsCo-Founder and scientific advisorcurrent2022 — presentUnited States
- Alloy Therapeutics, Inc.Chairman, Scientific Advisory Board, Genetic Medicinescurrent2022 — presentWaltham, Massachusetts, United States
- QurAlisMember, Scientific Advisory Boardcurrent2019 — present
- Dyne TherapeuticsMember, Scientific Advisory Boardcurrent2018 — present
- UMass Chan Medical SchoolAffiliate Professor in the Department of Medicinecurrent2021 — present
- UMass Chan Medical SchoolVisiting Professor in the Department of Medicine2018 — 2021Worcester, MA
- Harvard Medical School Initiative for RNA Medicine (HIRM)Member, Advisory Boardcurrent2017 — presentCambridge, MA
- SynGenisMember, Scientific Advisory Boardcurrent2021 — presentAustralia
- HAYA Therapeutics SAMember, Scientific Advisory Boardcurrent2021 — presentSwitzerland
- Bolden TherapeuticsScientific Advisor2020 — 2024Providence, Rhode Island, United States
- EnvisagenicsMember, Scientific Advisory Board2019 — 2024
- Maze TherapeuticsMember, Genetic therapy advisory board2021 — 2024
- Lytix BiopharmaMember, Scientific Advisory Board2018 — 2024Oslo Area, Norway
- Disarm Therapeutics (acquired by Lilly Company)Scientific Advisor2019 — 2022Cambridge, Massachusetts, United States
- Idera PharmaceuticalsPresident of Research2014 — 2017Cambridge, Massachusetts
- Idera PharmaceuticalsChief Executive Officer2004 — 2014Cambridge, Massachusetts
- Idera PharmaceuticalsChairman2010 — 2013Cambridge, Massachussetts
- Idera PharmaceuticalsChief Scientific Officer2000 — 2006Cambridge, Massachusetts
- Idera PharmaceuticalsFounding Scientist, Vice President of Discovery1989 — 2000Cambridge, Massachusetts
Skills & more
Biotechnology12Life Sciences9Molecular Biology8Pharmaceutical IndustryDrug DiscoveryDrug Development5Clinical Development3OncologyCancer5Clinical Trials3Biochemistry2Organic Chemistry3
+5 more
LifesciencesVaccinesTechnology TransferBiopharmaceuticalsImmunologyFrom Sudhir's professional profile.
Colleagues at 82VS
Andrei Ramirez-Valdez
Venture Associate at 82VS
Andrew Peterson
Founder / EIR at 82VS
Arthur Suckow
Investor at 82VS
Caitlin Tolman
Chief Operating Officer at 82VS
Carlos Loya
Venture Partner & Founder at 82VS
Colby Jordan
Vice President, Capital Formation at 82VS
Dongxing Zha
Founder / EIR at 82VS
Errik Anderson
Board Director at Basecamp Fund
Frequently asked questions
- Who is Sudhir Agrawal?
- Sudhir Agrawal is founder and president of ARNAY Sciences LLC, a life science research practice specializing in the chemical engineering of oligonucleotides for RNA therapeutic applications. Over 35 years, his research has focused on discovering and developing RNA therapeutics, with work in gapmer antisense, exon skipping, and immune modulation through toll-like receptors. His recent research explores transient spatial cyclic structures of nucleic acids for RNA therapeutic development.
- Where does Sudhir Agrawal work?
- Sudhir Agrawal is Advisor at 82VS.
- Where did Sudhir Agrawal go to school?
- Sudhir Agrawal studied at MRC Laboratory of Molecular Biology, Cambridge, UK (Post Doctoral Research, Nucleic Acids); Allahabad University, India (M.Sc, D. Phil.).
Founder mafias
82VS mafia8
Also came through, then founded or led a company.
Errik AndersonGeneral PartnerFounded Adimab +4Andrew PetersonFounder / EIRFounded Aldebaran Therapeutics +1Carlos LoyaVenture Partner & FounderFounded Aldebaran TherapeuticsMichael KalosAdvisorFounded IpiNovyx BioArthur SuckowAdvisorFounded DTx PharmaRoss LeimbergFounder / EIRFounded Cantai Therapeutics
+ 1 more
Dyne Therapeutics mafia4
Also came through, then founded or led a company.
Maze Therapeutics mafia3
Also came through, then founded or led a company.
Quralis mafia3
Also came through, then founded or led a company.
Haya Therapeutics mafia2
Also came through, then founded or led a company.
Shared employers
Also worked at Alloy Therapeutics, Inc.20
Jesse RobbinsFounder and Investor in AI Developer ToolsChaya PatelPrincipal at Mission BiocapitalErrik AndersonBoard Director at Basecamp FundAlasdair ThongFounding Partner at Selvedge VentureEsra BerkolChief of Staff at Selvedge VentureMike SchmidtGeneral Partner, President and Head of 82VS Boston at 82VS
+ 14 more
Also worked at Dyne Therapeutics5
Also worked at HAYA Therapeutics SA6
Gabriela EccoPrincipal at +ND CapitalBenjamin KreitmanPrincipal at Broadview VenturesThomas NeedhamDirector, Head of the Biopharma Practice at Broadview VenturesDaniel BertholetManaging Partner at 4see VenturesDr. Jens EcksteinAdvisor at Apollo Health VenturesSebastian BernalesGeneral Partner at Humboldt
